 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 123» |
- || Review, Journal: HER2 alterations in non-small cell lung cancer (NSCLC): from biology and testing to advances in treatment modalities. (Pubmed Central) - Jul 7, 2025
Furthermore, we present updated clinical trial data for published HER2-targeted agents and explore ongoing clinical trials examining combinatorial therapies and next-generation HER2-targeted agents such as zongertinib, A166, ARX788, SHRA1811, and others. Given the rapid evolution in this field, our review offers a timely and comprehensive synthesis of the current state and future directions for HER2-altered NSCLC.
- |||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P2 trial: A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer (clinicaltrials.gov) - Jul 7, 2025
P2, N=60, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P2 trial: SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression (clinicaltrials.gov) - Jul 2, 2025
P2, N=18, Not yet recruiting, Sponsor: Anhui Provincial Cancer Hospital
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC (clinicaltrials.gov) - Jul 2, 2025
P2, N=48, Not yet recruiting, Sponsor: Henan Cancer Hospital
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P2 trial: Efficacy and Safety of SHR-A1811 Followed by Dalpiciclib and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer (clinicaltrials.gov) - Jun 27, 2025
P2, N=45, Not yet recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Journal: SHR-A1811, a novel anti-HER2 antibody-drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles. (Pubmed Central) - Jun 26, 2025
The above results suggested that SHR-A1811 is a potential best-in-class anti-HER2 ADC with a highly permeable payload, optimized DAR, great potency and better safety profiles. Currently SHR-A1811 has entered phase II and phase III clinical studies for breast cancer, gastric cancer, colorectal cancer, and NSCLC.
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Perjeta (pertuzumab) / Roche
Enrollment open: SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC (clinicaltrials.gov) - Jun 26, 2025
P2, N=180, Recruiting, Sponsor: Henan Cancer Hospital
Currently SHR-A1811 has entered phase II and phase III clinical studies for breast cancer, gastric cancer, colorectal cancer, and NSCLC. Not yet recruiting --> Recruiting
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Journal: Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer. (Pubmed Central) - Jun 10, 2025
In the HR-positive subgroup, the closeness and aggregation of HER2-strong-positive tumor cells, as opposed to a uniform distribution, are linked to a lower response rate and HER2 luminal-like (HER2-LUM) subtype, which more closely resembles HR+/HER2- breast cancer. In addition, we develop a clinically practical predictive model capable of predicting neoadjuvant treatment responses to SHR-A1811 and other novel ADCs based on clinicopathological characteristics and pathological images.
- ||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment open: SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov) - Jun 6, 2025
P1/2, N=100, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
In addition, we develop a clinically practical predictive model capable of predicting neoadjuvant treatment responses to SHR-A1811 and other novel ADCs based on clinicopathological characteristics and pathological images. Not yet recruiting --> Recruiting
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Avastin (bevacizumab) / Roche
New P1/2 trial, Platinum sensitive: SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - May 27, 2025
P1/2, N=90, Not yet recruiting, Sponsor: Tongji Hospital
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P3 trial, Platinum resistant: SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov) - May 27, 2025
P3, N=300, Not yet recruiting, Sponsor: Tongji Hospital
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Airui'en (rezvilutamide) / Jiangsu Hengrui Pharma, tizetatug rezetecan (SHR-A1921) / Jiangsu Hengrui Pharma
Trial completion date, Trial primary completion date: A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing (clinicaltrials.gov) - May 23, 2025
P2, N=88, Recruiting, Sponsor: Fudan University
Not yet recruiting --> Recruiting Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Sep 2025 --> Dec 2025
- || trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
P2 data, Journal: Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase 2 trial. (Pubmed Central) - May 22, 2025
P2
This is the first study to report the efficacy and safety of third-generation HER2-directed ADC in the neoadjuvant setting for HER2-positive breast cancer. SHR-A1811 showed robust activity, with a tolerable safety profile.
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P2 trial: SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases (clinicaltrials.gov) - May 16, 2025
P2, N=60, Not yet recruiting, Sponsor: Wuhan Union Hospital, China
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P2 trial: A Phase II Study of SHR-A1811 Combined With Radiotherapy in HER2-positive and HER2-low Breast Cancer Brain Metastases (clinicaltrials.gov) - May 16, 2025
P2, N=30, Not yet recruiting, Sponsor: Wuhan Union Hospital, China
- trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Trastuzumab rezetecan in HER2-expressing advanced gastric cancer or gastroesophageal junction adenocarcinoma and colorectal cancer () - May 16, 2025 - Abstract #IGCC2025IGCC_230;
SHR-A1811 showed robust activity, with a tolerable safety profile. Trastuzumab rezetecan showed tolerable safety and preliminary efficacy in HER2-expressing advanced GC/GEJ and CRC.
- | New P2 trial: HER2-DM-NACT: This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy. (clinicaltrials.gov) - May 14, 2025
P2, N=30, Not yet recruiting, Sponsor: Hebei Medical University Fourth Hospital
- |||||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date: SHR-A1811-305: A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy (clinicaltrials.gov) - May 1, 2025
P3, N=1600, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Trastuzumab rezetecan showed tolerable safety and preliminary efficacy in HER2-expressing advanced GC/GEJ and CRC. Not yet recruiting --> Recruiting | N=1200 --> 1600
- trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
SHR-A1811 as neoadjuvant therapy for HR-positive, HER2-low breast cancer: A single-arm, phase II clinical study. (Hall A - Posters and Exhibits; Poster Bd #: 187) - May 1, 2025 - Abstract #ASCO2025ASCO_7414;
P2
These outcomes support further exploration of SHR-A1811 in this patient population. Clinical trial information: NCT05911958.
- Itovebi (inavolisib) / Roche
Enhanced efficacy of inavolisib combined with anti-PD-1 or anti-HER2 antibody in treating brain metastases from breast cancer. (Hall A - Posters and Exhibits; Poster Bd #: 87) - May 1, 2025 - Abstract #ASCO2025ASCO_7315;
This discovery provides new insights and possibilities for improving treatment options in breast cancer brain metastasis. Further research is needed to validate the efficacy and safety of this combination therapy.
- BB-1701 / BlissBio
A phase II study to evaluate the safety and efficacy of BB-1701 in subjects with HER2 expression locally advanced/metastatic breast cancer previously treated with HER2-ADC containing TOP-I inhibitor. (Hall A - Posters and Exhibits; Poster Bd #: 72) - May 1, 2025 - Abstract #ASCO2025ASCO_7314;
P
Clinical Trial Registration Number: CTR20241422 Background: BB-1701 is an HER2-targeting antibody-drug conjugate (ADC) containing eribulin...Among 8 HER2 low-expressioning (IHC 1+) patients, 3 patients achieved PR (2 patients received prior trastuzumab deruxtecan and 1 patient received prior SHR-A1811) and 4 patients had SD with DCR of 87.5%. BB-1701 shows promising antitumor activity and a manageable safety profile in HER2 expressing breast cancer patients who had previously been treated with HER2-ADC (containing TOP-I inhibitor).
- || trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment open, Platinum sensitive: A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - Apr 26, 2025
P1/2, N=50, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
BB-1701 shows promising antitumor activity and a manageable safety profile in HER2 expressing breast cancer patients who had previously been treated with HER2-ADC (containing TOP-I inhibitor). Not yet recruiting --> Recruiting
- trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
HER2-ADC trastuzumab rezetecan (SHR-A1811) in HER2-positive breast cancer with brain metastases: Update results from REIN trial. (Hall D2) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3413;
P2
Our findings showed that SHR-A1811 6.4 mg/kg solely or SHR-A1811 4.8 mg/kg combined with bevacizumab both can attain high intracranial remission rates, while the lower-dose combination regimen might exhibit a better safety profile. The long-term outcomes will continue to be followed up.
- trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
SHR-A1811 plus adebrelimab in unresectable or metastatic triple-negative breast cancer: Results from a phase 1b/2 expansion cohort. (Hall A - Posters and Exhibits; Poster Bd #: 82) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3320;
P2
The combination showed encouraging antitumor activity in unresectable or metastatic TNBC, irrespective of HER2 or PD-L1 expression status. Phase 2 preliminary efficacy summary.11HER2 and PD-L1 results were based on central lab assessment.
- trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
SHR-A1811 in patients (pts) with HER2-expressing advanced gynecological cancers (Gynecol C): A phase 2 study. (Hall A - Posters and Exhibits; Poster Bd #: 510) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2698;
P2
aIn pts with baseline and at least one post-baseline assessments; N was 41, 26, 33, 100, 37, 25, 31, and 93. bIn pts with confirmed CR or PR; N was 23, 13, 21, 57, 21, 13, 19, and 53.
- trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
SHR-A1811 in HER2-expressing salivary gland cancers: Preliminary efficacy and safety results. (S100a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1505;
P2
SHR-A1811 demonstrated promising efficacy in both HER2-positive and HER2-low advanced salivary gland cancers, achieving high ORRs and DCRs with an acceptable toxicity profile. Baseline characteristics.
- |||||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment open: SHR-A1811-307: A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Apr 21, 2025
P3, N=864, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Baseline characteristics. Not yet recruiting --> Recruiting
- ||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment closed, Enrollment change, Trial primary completion date: SHR-A1811-Ib/II-205: Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer (clinicaltrials.gov) - Apr 15, 2025
P2, N=76, Active, not recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Not yet recruiting --> Recruiting N=258 --> 76 | Trial primary completion date: Jul 2026 --> Apr 2025 | Recruiting --> Active, not recruiting
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Perjeta (pertuzumab) / Roche
New P2 trial: SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC (clinicaltrials.gov) - Apr 14, 2025
P2, N=180, Not yet recruiting, Sponsor: Henan Cancer Hospital
- || trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
P2 data, Journal, PD(L)-1 Biomarker, IO biomarker: Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study. (Pubmed Central) - Apr 3, 2025
P1/2
Trastuzumab rezetecan showed clinically meaningful activity and manageable safety in patients with previously treated HER2-mutant NSCLC. Further trials are justified.
- || trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment open: SHR-A1811-105: Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer (clinicaltrials.gov) - Mar 28, 2025
P1, N=32, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Further trials are justified. Not yet recruiting --> Recruiting
- trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
SHR-A1811, a HER2-directed antibody-drug conjugate (ADC), in advanced HER2-mutant non-small cell lung cancer (NSCLC): Updated phase 2 results from HORIZON-Lung (Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)) - Mar 25, 2025 - Abstract #AACR2025AACR_2098;
Not yet recruiting --> Recruiting Abstract is embargoed at this time.
- |||||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment open, Platinum resistant: A Study of SHR-A1811 in Subjects With Ovarian Cancer (clinicaltrials.gov) - Mar 24, 2025
P3, N=300, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Abstract is embargoed at this time. Not yet recruiting --> Recruiting
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial: MA-GC-II-023: Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping (clinicaltrials.gov) - Mar 18, 2025
P2, N=140, Not yet recruiting, Sponsor: China Medical University, China
- ||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment change: SHR-A1811-Ib/II-205: Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer (clinicaltrials.gov) - Mar 10, 2025
P2, N=258, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Not yet recruiting --> Recruiting N=156 --> 258
- ||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment open: A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Mar 5, 2025
P2, N=54, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
N=156 --> 258 Not yet recruiting --> Recruiting
- |||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P1/2 trial: SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov) - Mar 5, 2025
P1/2, N=100, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Journal: Trastuzumab rezetecan, a new antibody-drug conjugate in HER2-mutated NSCLC. (Pubmed Central) - Mar 1, 2025
Not yet recruiting --> Recruiting No abstract available
- |||||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment open: SHR-A1811-310: A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations (clinicaltrials.gov) - Feb 24, 2025
P3, N=300, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
No abstract available Not yet recruiting --> Recruiting
- || trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P1/2 trial, Platinum sensitive: A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - Feb 21, 2025
P1/2, N=50, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Updated efficacy and safety of SHR-A1811, an anti-HER2 antibody-drug conjugate, in heavily pretreated advanced solid tumors with HER2-expression or mutations: a global, multicenter, phase 1 study () - Feb 18, 2025 - Abstract #SGBCC2025SG_BCC_175;
- |||||||||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P3 trial, Platinum resistant: A Study of SHR-A1811 in Subjects With Ovarian Cancer (clinicaltrials.gov) - Feb 15, 2025
P3, N=300, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Enrollment open: Study of SHR-A1811 Combined with Pyrotinib and Bevacizumab in Advanced Breast Cancer with Brain Metastasis (clinicaltrials.gov) - Feb 6, 2025
P1/2, N=74, Recruiting, Sponsor: Fudan University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | HS-10352 / Jiangsu Hansoh Pharma, trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P1/2 trial: A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients (clinicaltrials.gov) - Jan 23, 2025
P1/2, N=52, Not yet recruiting, Sponsor: Henan Cancer Hospital
- |||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P2 trial: A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Jan 16, 2025
P2, N=54, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- | Trial primary completion date: FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov) - Dec 27, 2024
P2, N=716, Recruiting, Sponsor: Fudan University
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2024 --> Dec 2024
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P1/2 trial: Study of SHR-A1811 Combined with Pyrotinib and Bevacizumab in Advanced Breast Cancer with Brain Metastasis (clinicaltrials.gov) - Dec 5, 2024
P1/2, N=74, Not yet recruiting, Sponsor: Fudan University
- || trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P1 trial: SHR-A1811-105: Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer (clinicaltrials.gov) - Dec 2, 2024
P1, N=32, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||| HRS-8080 / Jiangsu Hengrui Pharma, ruzaltatug rezetecan (SHR-A2009) / Jiangsu Hengrui Pharma
Enrollment open: Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer (clinicaltrials.gov) - Nov 25, 2024
P1/2, N=350, Recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
Trial primary completion date: Sep 2024 --> Dec 2024 Not yet recruiting --> Recruiting
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Trial primary completion date: BC-NEO-IIT-SHR-A1811: A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer (clinicaltrials.gov) - Nov 4, 2024
P2, N=66, Recruiting, Sponsor: Henan Cancer Hospital
Not yet recruiting --> Recruiting Trial primary completion date: May 2024 --> Dec 2024